DEF 14A: Processa Pharmaceuticals Seeks Stockholder Approval for Incentive Plan Amendment at June 2024 Annual Meeting

Processa Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Omnibus Incentive Plan to increase the number of shares available for issuance by 500,000 at the Annual Meeting of Stockholders to be held June 28, 2024.

Summary

• Processa Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on June 28, 2024, at its corporate office in Hanover, MD.
• Stockholders will vote on several proposals, including the election of six directors, an amendment to the 2019 Omnibus Incentive Plan, ratification of the appointment of BD & Company, Inc. as the independent accounting firm, and an advisory vote on executive compensation.
• The key proposal involves amending the 2019 Omnibus Incentive Plan to increase the number of shares available for issuance by 500,000, bringing the total to 800,000 shares.
• This increase is intended to provide sufficient equity compensation to attract, retain, and motivate employees and directors.
• The board of directors recommends voting FOR all proposals.
• The company had 2,857,896 shares of common stock outstanding and entitled to vote as of the record date, April 29, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The positive sentiment stems from the company's efforts to attract and retain talent through equity compensation and the board's recommendation to vote FOR all proposals.

Positives

• The proposed increase in shares for the incentive plan aims to attract and retain key personnel, aligning their interests with those of stockholders.
• The company highlights several features of the incentive plan that protect stockholder interests, such as independent plan administration, no evergreen provision, and no repricing.
• The board emphasizes that using equity for retention and incentives is more effective than increasing cash compensation, reducing the impact on cash flow.
• The company's board of directors is diverse with one woman and four ethnically diverse directors.

Negatives

• Approval of the additional 500,000 shares would increase the overhang to 20.8% (as of April 22, 2024).

Risks

• If the stockholders do not approve the Amended Incentive Plan, the existing shares reserved for issuance under the Incentive Plan will be insufficient to achieve personnel incentive, recruiting and retention objectives, making it more difficult to meet these objectives.
• All outstanding stock options for 6,992 shares of common stock were underwater as of April 22, 2024.

Future Outlook

The company projects that the additional shares, if approved, will provide enough shares for future equity award grants for the next year.

Management Comments

• The Board believes that the Company must offer a competitive equity incentive program if it is to continue to successfully attract and retain the best possible candidates for positions within the Company.
• The Board expects that the Additional Shares under our Amended Incentive Plan will be vital in continuing to attract, retain and reward high caliber employees who are essential to our success and to provide incentives to these individuals to promote the success of the Company thereby aligning their interests with the interests of the Companys stockholders.

Industry Context

The document does not explicitly discuss broader industry trends, but the need to attract and retain talent with competitive equity compensation is a common theme in the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards for equity compensation.
• However, it mentions that the compensation committee considers market standards and trends when setting executive compensation.
• The document mentions several comparable companies where Processa's executives and directors also serve, including Calidi Biotherapeutics Inc. (NYSE:CLDI), Longeveron, Poxel S.A. (OTC: PXXLF), XOMA Corporation (Nasdaq: XOMA), Royal Business Bank (Nasdaq: RBB), Palisade Bio, Inc., and Monterey Bio.

Related Party Transactions

• CorLyst, LLC, reimburses Processa for shared costs related to payroll, health insurance, and rent based on actual costs incurred.
• Processa recorded $112,000 and $124,000 in reimbursements from CorLyst during the years ended December 31, 2023 and 2022, respectively.
• Dr. Young, President, Research and Development, is the CEO of CorLyst.

Stakeholder Impact

• Approval of the incentive plan amendment could positively impact employees and directors by providing them with equity compensation.
• Stockholders could benefit from the alignment of management's interests with long-term value creation.
• Failure to approve the amendment could negatively impact the company's ability to attract and retain talent, potentially affecting its performance.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 28, 2024, to conduct the votes.
• The company will announce the voting results in a Form 8-K within four business days following the annual meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Incentive Plan, Executive Compensation, Board of Directors, Stockholders, Shares, Processa Pharmaceuticals